ID   Mero-84
AC   CVCL_2596
SY   MERO84
DR   cancercelllines; CVCL_2596
DR   Cell_Model_Passport; SIDM01905
DR   DepMap; ACH-001561
DR   ECACC; 09100107
DR   Wikidata; Q54905215
RX   PubMed=2474517;
RX   PubMed=25902174;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: ~48 hours (ECACC=09100107).
CC   Omics: Deep exome analysis.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): DepMap; ECACC
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 8,12
ST   D16S539: 9
ST   D18S51: 15,16
ST   D21S11: 29,31,32
ST   D3S1358: 16
ST   D5S818: 11
ST   D7S820: 9,11 (ECACC)
ST   D7S820: 9,11,12 (DepMap)
ST   D8S1179: 12
ST   FGA: 19
ST   Penta D: 10,13
ST   Penta E: 7,11
ST   TH01: 9
ST   TPOX: 9,11
ST   vWA: 14,17
DI   NCIt; C45665; Pleural biphasic mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 18
//
RX   PubMed=2474517; DOI=10.1002/ijc.2910440212;
RA   Versnel M.A., Bouts M.J., Hoogsteden H.C., van der Kwast T.H.,
RA   Delahaye M., Hagemeijer A.;
RT   "Establishment of human malignant mesothelioma cell lines.";
RL   Int. J. Cancer 44:256-260(1989).
//
RX   PubMed=25902174; DOI=10.1097/JTO.0000000000000493;
RA   Miyanaga A., Masuda M., Tsuta K., Kawasaki K., Nakamura Y., Sakuma T.,
RA   Asamura H., Gemma A., Yamada T.;
RT   "Hippo pathway gene mutations in malignant mesothelioma: revealed by
RT   RNA and targeted exon sequencing.";
RL   J. Thorac. Oncol. 10:844-851(2015).
//